US › Healthcare

Tevogen Bio Holdings Inc. (TVGN)

US · Healthcare · Biotechnology

$7.71-1.15%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.8M

EPS

$-1.52

EPS estimate

$-2.50

EPS came in at -1.52 against a street estimate of -2.50 — a beat of 39.2%.

Key statistics

Market cap

$47.9M

Forward P/E

0.0

P/B

0.00

Book value

$-4.47

EPS (TTM)

$-6.29

52-week high

$43.65

52-week low

$3.64

50-day MA

$6.14

200-day MA

$10.39

Beta

0.19

Analyst view

Analysts rate Tevogen Bio Holdings Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $2.00.

Shareholding

Insiders

67.16%

Institutions

1.65%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	0.52%
BlackRock Inc	0.38%
Morgan Stanley - Brokerage Accounts	0.27%
Geode Capital Management, LLC	0.25%
Deutsche Bank AG	0.24%
FMR Inc	0.16%
Vanguard Portfolio Management, LLC	0.07%
UBS Group AG	0.06%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tevogen Bio Holdings Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.